We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $1.06B
1-Year Est. Return 52.03%
This Fund
S&P 500
This Quarter Est. Return
+22.03%
1 Year Est. Return
+52.03%
3 Year Est. Return
+131.18%
5 Year Est. Return
+187.67%
10 Year Est. Return
+1,140.82%
AUM
$1.06B
AUM Growth
+$249M
Cap. Flow
+$137M
Cap. Flow %
12.89%
Top 10 Hldgs %
25.08%
Holding
106
New
20
Increased
41
Reduced
34
Closed
7

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$28.5M
2
MRK icon
Merck
MRK
+$25M
3
UNH icon
UnitedHealth
UNH
+$17.8M
4
JNJ icon
Johnson & Johnson
JNJ
+$16.9M
5
CNC icon
Centene
CNC
+$13M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.1M
2
LLY icon
Eli Lilly
LLY
+$11.6M
3
VEEV icon
Veeva Systems
VEEV
+$11.2M
4
ADPT icon
Adaptive Biotechnologies
ADPT
+$9.99M
5
BSX icon
Boston Scientific
BSX
+$9.48M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MEDP icon
76
Medpace
MEDP
$17.3B
$4.5M 0.42%
+8,500
New +$3.92M
MDGL icon
77
Madrigal Pharmaceuticals
MDGL
$11.9B
$4.32M 0.41%
8,050
-16,000
-67% -$8.2M
AMGN icon
78
Amgen
AMGN
$224B
$4.31M 0.41%
11,900
-3,300
-22% -$1.13M
SION
79
Sionna Therapeutics
SION
$236M
$4.27M 0.4%
97,100
+9,600
+11% +$384K
ASND icon
80
Ascendis Pharma A/S
ASND
$14.8B
$4M 0.38%
15,000
– –
COO icon
81
Cooper Companies
COO
$10.5B
$3.87M 0.37%
54,000
+4,000
+8% +$261K
WAY
82
Waystar Holding Corp
WAY
$4.74B
$3.67M 0.35%
178,566
-164,000
-48% -$3.45M
MBX
83
MBX Biosciences
MBX
$2.58B
$3.42M 0.32%
+62,000
New +$2.17M
VCEL icon
84
Vericel Corp
VCEL
$2.03B
$3.11M 0.29%
70,000
– –
VEEV icon
85
Veeva Systems
VEEV
$45.4B
$3.07M 0.29%
17,300
-68,000
-80% -$11.2M
BCAX
86
Bicara Therapeutics
BCAX
$1.27B
$2.62M 0.25%
+88,150
New +$1.97M
STE icon
87
Steris
STE
$20.4B
$2.42M 0.23%
11,500
– –
OCUL icon
88
Ocular Therapeutix
OCUL
$2.12B
$2.21M 0.21%
225,000
-80,000
-26% -$725K
STOK icon
89
Stoke Therapeutics
STOK
$1.6B
$2.11M 0.2%
64,500
-18,500
-22% -$594K
XENE icon
90
Xenon Pharmaceuticals
XENE
$3.58B
$2.01M 0.19%
33,250
+5,250
+19% +$291K
DOCS icon
91
Doximity
DOCS
$4.7B
$1.58M 0.15%
76,107
-107,701
-59% -$2.38M
PRVA icon
92
Privia Health
PRVA
$2.52B
$1.29M 0.12%
+50,000
New +$1.16M
NVCR icon
93
NovoCure
NVCR
$1.84B
$1.06M 0.1%
70,000
– –
MMED
94
MiniMed Group Inc
MMED
$5.62B
$822K 0.08%
+55,000
New +$725K
ATEC icon
95
Alphatec Holdings
ATEC
$1.56B
$735K 0.07%
85,000
+15,000
+21% +$137K
AGL icon
96
Agilon Health
AGL
$1.36B
$536K 0.05%
+5,000
New +$327K
TXG icon
97
10x Genomics
TXG
$11.2B
$326K 0.03%
+8,500
New +$223K
TNDM icon
98
Tandem Diabetes Care
TNDM
$1.09B
$302K 0.03%
+20,000
New +$349K
TGTX icon
99
TG Therapeutics
TGTX
$8.79B
$275K 0.03%
+5,000
New +$205K
ADPT icon
100
Adaptive Biotechnologies
ADPT
$4.7B
– –
-720,000
Closed -$9.99M
1 2 3
4
5

Similar funds

JSC
J. Stern & Co London, United Kingdom $1.06B AUM 11.76% 1-Year Est. Return
PCI
Planning Center Inc Moline, Illinois $1.06B AUM 12.82% 1-Year Est. Return
SAM
Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return
BDP
Brehaut David Pascal $1.06B AUM
GX
Greylock XIV Menlo Park, California $1.06B AUM
CIC
Cutler Investment Counsel Jacksonville, Oregon $1.06B AUM 20.29% 1-Year Est. Return
RCIM
Red Cedar Investment Management Grand Rapids, Michigan $1.06B AUM 30.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Rhenman & Partners Asset Management held 106 positions worth $1.06B, up 31% from $810M the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rhenman & Partners Asset Management deployed $137M of net new capital in Q2 2026, opening 20 new positions and adding to 41 existing holdings. Its largest new stake was AstraZeneca: 151,500 shares worth $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $14.1M trimmed.

  • Rhenman & Partners Asset Management's largest Q2 2026 buy was AstraZeneca: 151,500 shares worth $28.5M.
  • Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2026, an estimated $17.8M increase.
  • Rhenman & Partners Asset Management's biggest Q2 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $14.1M.
  • Rhenman & Partners Asset Management fully exited Adaptive Biotechnologies in Q2 2026, selling an estimated $9.99M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 25% of its $1.06B portfolio in Q2 2026.
  • Rhenman & Partners Asset Management opened 20 new positions and closed 7 in Q2 2026.
  • Rhenman & Partners Asset Management's portfolio value rose 31% quarter-over-quarter to $1.06B.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.